vs
Side-by-side financial comparison of BENCHMARK ELECTRONICS INC (BHE) and Jazz Pharmaceuticals plc (JAZZ). Click either name above to swap in a different company.
Jazz Pharmaceuticals plc is the larger business by last-quarter revenue ($1.2B vs $725.8M, roughly 1.7× BENCHMARK ELECTRONICS INC). On growth, Jazz Pharmaceuticals plc posted the faster year-over-year revenue change (10.1% vs 6.2%). Jazz Pharmaceuticals plc produced more free cash flow last quarter ($345.8M vs $48.2M). Over the past eight quarters, Jazz Pharmaceuticals plc's revenue compounded faster (15.2% CAGR vs 1.1%).
Benchmark Electronics Inc is an EMS, ODM, and OEM company based in Tempe, Arizona in the Phoenix metropolitan area. It provides contract manufacturing services.
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
BHE vs JAZZ — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $725.8M | $1.2B |
| Net Profit | — | $203.5M |
| Gross Margin | 10.2% | — |
| Operating Margin | 2.8% | 21.2% |
| Net Margin | — | 17.0% |
| Revenue YoY | 6.2% | 10.1% |
| Net Profit YoY | — | 6.5% |
| EPS (diluted) | $0.16 | $3.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $725.8M | $1.2B | ||
| Q3 25 | $702.6M | $1.1B | ||
| Q2 25 | $665.7M | $1.0B | ||
| Q1 25 | $654.6M | $897.8M | ||
| Q4 24 | $683.6M | $1.1B | ||
| Q3 24 | $680.0M | $1.1B | ||
| Q2 24 | $686.7M | $1.0B | ||
| Q1 24 | $710.6M | $902.0M |
| Q4 25 | — | $203.5M | ||
| Q3 25 | $14.3M | $251.4M | ||
| Q2 25 | $972.0K | $-718.5M | ||
| Q1 25 | $3.6M | $-92.5M | ||
| Q4 24 | — | $191.1M | ||
| Q3 24 | $15.4M | $215.1M | ||
| Q2 24 | $15.5M | $168.6M | ||
| Q1 24 | $14.0M | $-14.6M |
| Q4 25 | 10.2% | — | ||
| Q3 25 | 9.7% | — | ||
| Q2 25 | 9.7% | — | ||
| Q1 25 | 9.7% | — | ||
| Q4 24 | 9.9% | — | ||
| Q3 24 | 9.8% | — | ||
| Q2 24 | 9.9% | — | ||
| Q1 24 | 9.5% | — |
| Q4 25 | 2.8% | 21.2% | ||
| Q3 25 | 3.4% | 5.1% | ||
| Q2 25 | 3.1% | -65.6% | ||
| Q1 25 | 1.8% | -6.2% | ||
| Q4 24 | 4.2% | 17.5% | ||
| Q3 24 | 4.1% | 24.7% | ||
| Q2 24 | 4.0% | 19.5% | ||
| Q1 24 | 3.6% | 7.3% |
| Q4 25 | — | 17.0% | ||
| Q3 25 | 2.0% | 22.3% | ||
| Q2 25 | 0.1% | -68.7% | ||
| Q1 25 | 0.6% | -10.3% | ||
| Q4 24 | — | 17.6% | ||
| Q3 24 | 2.3% | 20.4% | ||
| Q2 24 | 2.3% | 16.5% | ||
| Q1 24 | 2.0% | -1.6% |
| Q4 25 | $0.16 | $3.34 | ||
| Q3 25 | $0.39 | $4.08 | ||
| Q2 25 | $0.03 | $-11.74 | ||
| Q1 25 | $0.10 | $-1.52 | ||
| Q4 24 | $0.43 | $2.97 | ||
| Q3 24 | $0.42 | $3.42 | ||
| Q2 24 | $0.43 | $2.49 | ||
| Q1 24 | $0.38 | $-0.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.1M | $1.4B |
| Total DebtLower is stronger | $206.8M | $5.4B |
| Stockholders' EquityBook value | $1.1B | $4.3B |
| Total Assets | $2.1B | $11.7B |
| Debt / EquityLower = less leverage | 0.19× | 1.24× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $322.1M | $1.4B | ||
| Q3 25 | $285.4M | $1.3B | ||
| Q2 25 | $264.6M | $1.2B | ||
| Q1 25 | $355.3M | $1.9B | ||
| Q4 24 | $315.2M | $2.4B | ||
| Q3 24 | $324.4M | $2.2B | ||
| Q2 24 | $309.3M | $1.4B | ||
| Q1 24 | $296.1M | $1.4B |
| Q4 25 | $206.8M | $5.4B | ||
| Q3 25 | $212.6M | $5.4B | ||
| Q2 25 | $203.4M | $5.4B | ||
| Q1 25 | $268.9M | $5.4B | ||
| Q4 24 | $250.5M | $6.1B | ||
| Q3 24 | $272.0M | $6.1B | ||
| Q2 24 | $283.6M | $5.7B | ||
| Q1 24 | $310.1M | $5.7B |
| Q4 25 | $1.1B | $4.3B | ||
| Q3 25 | $1.1B | $4.0B | ||
| Q2 25 | $1.1B | $3.7B | ||
| Q1 25 | $1.1B | $4.2B | ||
| Q4 24 | $1.1B | $4.1B | ||
| Q3 24 | $1.1B | $4.2B | ||
| Q2 24 | $1.1B | $3.8B | ||
| Q1 24 | $1.1B | $3.7B |
| Q4 25 | $2.1B | $11.7B | ||
| Q3 25 | $2.1B | $11.4B | ||
| Q2 25 | $2.0B | $10.9B | ||
| Q1 25 | $2.1B | $11.5B | ||
| Q4 24 | $2.1B | $12.0B | ||
| Q3 24 | $2.1B | $12.3B | ||
| Q2 24 | $2.2B | $11.4B | ||
| Q1 24 | $2.2B | $11.3B |
| Q4 25 | 0.19× | 1.24× | ||
| Q3 25 | 0.19× | 1.35× | ||
| Q2 25 | 0.18× | 1.45× | ||
| Q1 25 | 0.24× | 1.29× | ||
| Q4 24 | 0.23× | 1.49× | ||
| Q3 24 | 0.25× | 1.47× | ||
| Q2 24 | 0.26× | 1.52× | ||
| Q1 24 | 0.29× | 1.54× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $58.7M | $362.5M |
| Free Cash FlowOCF − Capex | $48.2M | $345.8M |
| FCF MarginFCF / Revenue | 6.6% | 28.9% |
| Capex IntensityCapex / Revenue | 1.4% | 1.4% |
| Cash ConversionOCF / Net Profit | — | 1.78× |
| TTM Free Cash FlowTrailing 4 quarters | $88.4M | $1.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $58.7M | $362.5M | ||
| Q3 25 | $36.6M | $474.6M | ||
| Q2 25 | $-2.8M | $88.9M | ||
| Q1 25 | $31.5M | $429.8M | ||
| Q4 24 | $45.9M | $398.6M | ||
| Q3 24 | $39.0M | $398.7M | ||
| Q2 24 | $55.8M | $331.4M | ||
| Q1 24 | $48.5M | $267.2M |
| Q4 25 | $48.2M | $345.8M | ||
| Q3 25 | $25.8M | $459.4M | ||
| Q2 25 | $-13.8M | $75.9M | ||
| Q1 25 | $28.1M | $415.9M | ||
| Q4 24 | $37.2M | $385.3M | ||
| Q3 24 | $29.2M | $388.0M | ||
| Q2 24 | $48.2M | $324.3M | ||
| Q1 24 | $43.3M | $260.3M |
| Q4 25 | 6.6% | 28.9% | ||
| Q3 25 | 3.7% | 40.8% | ||
| Q2 25 | -2.1% | 7.3% | ||
| Q1 25 | 4.3% | 46.3% | ||
| Q4 24 | 5.4% | 35.4% | ||
| Q3 24 | 4.3% | 36.8% | ||
| Q2 24 | 7.0% | 31.7% | ||
| Q1 24 | 6.1% | 28.9% |
| Q4 25 | 1.4% | 1.4% | ||
| Q3 25 | 1.5% | 1.3% | ||
| Q2 25 | 1.7% | 1.2% | ||
| Q1 25 | 0.5% | 1.5% | ||
| Q4 24 | 1.3% | 1.2% | ||
| Q3 24 | 1.4% | 1.0% | ||
| Q2 24 | 1.1% | 0.7% | ||
| Q1 24 | 0.7% | 0.8% |
| Q4 25 | — | 1.78× | ||
| Q3 25 | 2.57× | 1.89× | ||
| Q2 25 | -2.90× | — | ||
| Q1 25 | 8.65× | — | ||
| Q4 24 | — | 2.09× | ||
| Q3 24 | 2.54× | 1.85× | ||
| Q2 24 | 3.59× | 1.97× | ||
| Q1 24 | 3.46× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BHE
| Other | $384.9M | 53% |
| Aerospace And Defense Sector | $107.6M | 15% |
| Healthcare Sector | $81.7M | 11% |
| Advanced Computing And Communications Sector | $70.0M | 10% |
| Semi Cap Sector | $45.4M | 6% |
| Industrial Sector | $25.2M | 3% |
| Intersegment Sales | $11.0M | 2% |
JAZZ
| Xywav | $465.5M | 39% |
| Total Oncology | $337.8M | 28% |
| Rylaze Enrylaze | $108.2M | 9% |
| Zepzelca | $90.4M | 8% |
| Product And Services Royalties And Contract Revenue | $65.5M | 5% |
| High Sodium AG Oxybate Product Royalty Revenue | $55.7M | 5% |
| Xyrem | $37.8M | 3% |
| Vyxeos | $34.7M | 3% |
| Ziihera | $8.5M | 1% |
| Other Products | $2.8M | 0% |
| Sativex | $1.5M | 0% |
